הומלוג - Humalog

הומלוג קוויקפן הומלוג קוויקפן

Product Description

Overview

The primary activity of insulin lispro is the regulation of glucose metabolism.

Insulin lispro has a rapid onset of action (approximately 15 minutes), thus allowing it to be given closer to a meal (within zero to 15 minutes of the meal) when compared to regular insulin (30 to 45 minutes before). Insulin lispro takes effect rapidly and has a shorter duration of activity (2 to 5 hours) when compared to regular insulin.

Clinical trials in patients with type 1 and type 2 diabetes have demonstrated reduced postprandial hyperglycemia with insulin lispro compared to soluble human insulin.

As with all insulin preparations, the time course of insulin lispro action may vary in different individuals or at different times in the same individual and is dependent on dose, site of injection, blood supply, temperature and physical activity.

Therapeutic indications - Israel

For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilization of diabetes mellitus.

מסגרת הכללה בסל: התרופה האמורה תינתן לטיפול בחולי סוכרת

Method of administration

The dosage should be determined by the physician, according to the requirement of the patient.Humalog may be given shortly before meals. When necessary Humalog can be given soon after meals. Humalog preparations should be given by subcutaneous injection or by continuous subcutaneous infusion pump and may, although not recommended, also be given by intramuscular injection. If necessary, Humalog may also be administered intravenously, for example; for the control of blood glucose levels during ketoacidosis, acute illnesses or during intra and post-operative periods.

Contraindications

Hypersensitivity to insulin lispro or to any of the excipients.
Hypoglycaemia

לעלון לרופא ולעלון לצרכן באתר משרד הבריאות אנא לחץ כאן: Humalog הומלוג: Insulin Lispro


Insulin Lispro PI, Ministry of Health approved in September 2011.

למעלה
MTM5OTIy,MTM5OTc3,MTM5MDE0,MTM5OTUz,MTM5NjAx,MTM5NjMy,MTM5Mzk3,MTM5NDQx,MTM5NDQx,MTM5Njk0,MTM5NzQ4,MTM5NjQ5,MTM5ODky,MTM5NDEw,MTM5OTQ2,MTM5NDY1,MTM5OTkx,MTM5MDA0,MTM5MDEx,IDEzOTY0OQ==
MjAxNw==
MTM5OTIy-,MTM5OTc3-,MTM5MDE0-,MTM5OTUz-,MTM5NjAx-,MTM5NjMy-,MTM5Mzk3-L2hlL3Byb2R1Y3QvcGF0aWVudC90cnVsaWNpdHkvaW5kZXguYXNweA==,MDY3Njc2-,MTM5NzE3-,MTM5OTE1-,MTM5MDIx-,MTM5Njg3-,MTM5NzMx-,MTM5Nzg2-,MTM5NDQx-L2hlL3Byb2R1Y3QvcGF0aWVudC90cnVsaWNpdHkvaW5kZXguYXNweA==,MTM5NjQ5-L2hlL3Byb2R1Y3QvcGF0aWVudC9odW1hbG9nLWt3aWtwZW4tMjAwL2luZGV4LmFzcHg=,MTM5ODky-L2hlL3Byb2R1Y3QvcGF0aWVudC9zdHJhdHRlcmEvaW5kZXguYXNweA==,MTM5NDEw-L2hlL3Byb2R1Y3QvcGF0aWVudC9zdHJhdHRlcmEvaW5kZXguYXNweA==,MTM5OTQ2-L2hlL3Byb2R1Y3QvcGF0aWVudC9zdHJhdHRlcmEvaW5kZXguYXNweA==,MTM5NDY1-L2hlL3Byb2R1Y3QvcGF0aWVudC9zdHJhdHRlcmEvaW5kZXguYXNweA==,MTM5OTkx-L2hlL3Byb2R1Y3QvcGF0aWVudC9zdHJhdHRlcmEvaW5kZXguYXNweA==,MTM5MDA0-L2hlL3Byb2R1Y3QvcGF0aWVudC9zdHJhdHRlcmEvaW5kZXguYXNweA==,MTM5MDEx-L2hlL3Byb2R1Y3QvcGF0aWVudC9zdHJhdHRlcmEvaW5kZXguYXNweA==,MTM5Njk0-L2hlL3Byb2R1Y3QvcGF0aWVudC9iYXNhZ2xhci9pbmRleC5hc3B4,MTM5NzQ4-L2hlL3Byb2R1Y3QvcGF0aWVudC9iYXNhZ2xhci9pbmRleC5hc3B4,MTM5NjQ5-L2hlL3Byb2R1Y3QvcGF0aWVudC9odW1hbG9nLWt3aWtwZW4tMjAwL2luZGV4LmFzcHg=